Prognostic Significance of New Immunohistochemical Markers in Refractory Classical Hodgkin Lymphoma: a Study of 59 Cases

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2009 Jul 23

PMID 19623262

Citations 12

Authors

Danielle Canioni

Benedicte Deau-Fischer

Pierre Taupin

Vincent Ribrag

Richard Delarue

Jacques Bosq

Marie-Therese Rubio

Damien Roux

Viorel Vasiliu

Bruno Varet

Nicole Brousse

Olivier Hermine

Affiliations

Soon will be listed here.

Abstract

Although most classical Hodgkin lymphoma patients are cured, a significant minority fail after primary therapy and may die as result of their disease. To date, there is no consensus on biological markers that add value to usual parameters (which comprise the International Prognostic Score) used at diagnosis to predict outcome. We evaluated 59 patients (18 with primary refractory or early relapse disease and 41 responders) for bcl2, Ki67, CD20, TiA1 and c-kit expression by semi-quantitative immunohistochemical study and correlated the results with the response to treatment.The results showed that expression of bcl2 and CD20 in Hodgkin and Reed Sternberg cells, and expression of TiA1 in micro-environmental lymphocytes, and c-kit positive mast cells in microenvironment, were independent prognostic markers. These novel cHL markers could be used in association with clinical parameters to identify newly diagnosed patients with favorable or unfavorable prognosis and to better tailor treatment for different risk groups.

Citing Articles

Patients with Classical Hodgkin Lymphoma with Less Than 10.5 CD20-Positive Reed-Sternberg Cells in 10 High-Power Fields Have Better Prognosis.

Lacet D, Oliveira C Indian J Hematol Blood Transfus. 2022; 38(3):596-600.

PMID: 35747562 PMC: 9209577. DOI: 10.1007/s12288-021-01517-7.

Steering Mast Cells or Their Mediators as a Prospective Novel Therapeutic Approach for the Treatment of Hematological Malignancies.

Mehtani D, Puri N Front Oncol. 2021; 11:731323.

PMID: 34631562 PMC: 8497976. DOI: 10.3389/fonc.2021.731323.

CD163 is a predictive biomarker for prognosis of classical Hodgkin's lymphoma in Saudi patients.

Ahmed H, Raslan W, Deifalla A, Fathallah M Mol Clin Oncol. 2019; 11(1):67-76.

PMID: 31289681 PMC: 6535641. DOI: 10.3892/mco.2019.1850.

ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma.

Winkfield K, Advani R, Ballas L, Dabaja B, Dhakal S, Flowers C Oncology (Williston Park). 2016; 30(12):1099-103, 1106-8.

PMID: 27987203 PMC: 7440297.

CD20 Over-Expression in Hodgkin-Reed-Sternberg Cells of Classical Hodgkin Lymphoma: the Neglected Quest.

Benharroch D, Nalbandyan K, Lazarev I J Cancer. 2015; 6(11):1155-9.

PMID: 26516364 PMC: 4615352. DOI: 10.7150/jca.13107.

References

Fischer M, Juremalm M, Olsson N, Backlin C, Sundstrom C, Nilsson K . Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int J Cancer. 2003; 107(2):197-201. DOI: 10.1002/ijc.11370. View

Skinnider B, Elia A, Gascoyne R, Trumper L, von Bonin F, Kapp U . Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2001; 97(1):250-5. DOI: 10.1182/blood.v97.1.250. View

Spector N, Milito C, Biasoli I, Luiz R, Pulcheri W, Morais J . The prognostic value of the expression of Bcl-2, p53 and LMP-1 in patients with Hodgkin's lymphoma. Leuk Lymphoma. 2005; 46(9):1301-6. DOI: 10.1080/10428190500126034. View

Pinto A, Aldinucci D, Gloghini A, Zagonel V, Degan M, Improta S . Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood. 1996; 88(9):3299-305. View

Brink A, Oudejans J, van den Brule A, Kluin P, Horstman A, Ossenkoppele G . Low p53 and high bcl-2 expression in Reed-Sternberg cells predicts poor clinical outcome for Hodgkin's disease: involvement of apoptosis resistance?. Mod Pathol. 1998; 11(4):376-83. View

Anderlini P, Saliba R, Acholonu S, Okoroji G, Donato M, Giralt S . Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant. 2005; 35(10):943-51. DOI: 10.1038/sj.bmt.1704942. View

Alvaro-Naranjo T, Lejeune M, Salvado-Usach M, Bosch-Princep R, Reverter-Branchat G, Jaen-Martinez J . Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients. Leuk Lymphoma. 2005; 46(11):1581-91. DOI: 10.1080/10428190500220654. View

Hahn T, Benekli M, Wong C, Moysich K, Hyland A, Michalek A . A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease. Bone Marrow Transplant. 2005; 35(6):557-66. DOI: 10.1038/sj.bmt.1704789. View

Alvaro T, Lejeune M, Salvado M, Bosch R, Garcia J, Jaen J . Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005; 11(4):1467-73. DOI: 10.1158/1078-0432.CCR-04-1869. View

10.

Tzankov A, Krugmann J, Fend F, Fischhofer M, Greil R, Dirnhofer S . Prognostic significance of CD20 expression in classical Hodgkin lymphoma: a clinicopathological study of 119 cases. Clin Cancer Res. 2003; 9(4):1381-6. View

11.

Dillman R . Monoclonal antibody therapy for lymphoma: an update. Cancer Pract. 2002; 9(2):71-80. DOI: 10.1046/j.1523-5394.2001.009002071.x. View

12.

Kashkar H, Kronke M, Jurgensmeier J . Defective Bax activation in Hodgkin B-cell lines confers resistance to staurosporine-induced apoptosis. Cell Death Differ. 2002; 9(7):750-7. DOI: 10.1038/sj.cdd.4401024. View

13.

Montalban C, Garcia J, Abraira V, Gonzalez-Camacho L, Morente M, Bello J . Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group. J Clin Oncol. 2004; 22(9):1664-73. DOI: 10.1200/JCO.2004.06.105. View

14.

Portlock C, Donnelly G, Qin J, Straus D, Yahalom J, Zelenetz A . Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease. Br J Haematol. 2004; 125(6):701-8. DOI: 10.1111/j.1365-2141.2004.04964.x. View

15.

Akin C, Metcalfe D . The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol. 2004; 114(1):13-9. DOI: 10.1016/j.jaci.2004.04.046. View

16.

Lavoie J, Connors J, Phillips G, Reece D, Barnett M, Forrest D . High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood. 2005; 106(4):1473-8. DOI: 10.1182/blood-2004-12-4689. View

17.

Molot R, Mendenhall N, Barre D, Braylan R . The clinical relevance of L26, a B-cell-specific antibody, in Hodgkin's disease. Am J Clin Oncol. 1994; 17(3):185-8. DOI: 10.1097/00000421-199406000-00001. View

18.

Garcia J, Camacho F, Morente M, Fraga M, Montalban C, Alvaro T . Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood. 2002; 101(2):681-9. DOI: 10.1182/blood-2002-04-1128. View

19.

Diehl V, Stein H, Hummel M, Zollinger R, Connors J . Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology Am Soc Hematol Educ Program. 2003; :225-47. DOI: 10.1182/asheducation-2003.1.225. View

20.

Marafioti T, Hummel M, Foss H, Laumen H, Korbjuhn P, Anagnostopoulos I . Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood. 2000; 95(4):1443-50. View